Time dependent pharmacokinetics of albendazole in human
- 1 July 2003
- journal article
- clinical trial
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 24 (5) , 199-204
- https://doi.org/10.1002/bdd.355
Abstract
The pharmacokinetics of the main metabolites of albendazole (albendazole sulphoxide (ABZ‐SO) and albendazole sulphone (ABZ‐SO2)) were studied in 12 healthy human volunteers in a double blind design on the first and last days of oral administration of 800 mg albendazole daily for 15 days. No significant differences were observed in Cmax, Tmax and Vd/F of ABZ‐SO, whereas the AUC, AUMC and T1/2 of this metabolite were significantly reduced and Cl/F was significantly increased in multiple dosing. There were also no significant differences in the Cmax, Tmax, Vd/F and T1/2 of ABZ‐SO2, whereas the AUC and AUMC of this metabolite were significantly reduced and Cl/F was significantly increased in multiple dosing. These observations suggest time dependent pharmacokinetics of albendazole (observed for ABZ‐SO and ABZ‐SO2), which was explained on the basis of the induction of enzymes involved in the metabolism of ABZ‐SO (albendazole sulphoxide) to metabolites other than albendazole sulphone in multiple dosing. Copyright © 2003 John Wiley & Sons, Ltd.Keywords
This publication has 13 references indexed in Scilit:
- A high performance liquid chromatography method for simultaneous determination of albendazole metabolites in human serumJournal of Pharmaceutical and Biomedical Analysis, 2002
- Effect of dose increase or cimetidine co-administration on albendazole bioavailability.The American Journal of Tropical Medicine and Hygiene, 2000
- The pharmacokinetics of albendazole metabolites following administration of albendazole, albendazole sulfoxide and netobimin to one-month- and eight-month-old sheepInternational Journal for Parasitology, 1995
- Clinical Pharmacokinetics of Albendazole in Patients with Brain CysticercosisThe Journal of Clinical Pharmacology, 1992
- Plasma and CSF Levels of Albendazole and Praziquantel in Patients with NeurocysticercosisClinical Neuropharmacology, 1990
- Albendazole treatment of echinococcosis in humans: Effects on microsomal metabolism and drug toleranceClinical Pharmacology & Therapeutics, 1990
- Study of the in vitro bioactivation of albendazole in human liver microsomes and hepatoma cell linesCell Biology and Toxicology, 1989
- Increased systemic availability of albendazole when taken with a fatty mealEuropean Journal of Clinical Pharmacology, 1988
- Inducing effect of albendazole on rat liver drug-metabolizing enzymes and metabolite pharmacokineticsToxicology and Applied Pharmacology, 1988
- A correlation of toxicity of albendazole and oxfendazole with their free metabolites and bound residuesJournal of Veterinary Pharmacology and Therapeutics, 1984